
XAIR Stock Forecast & Price Target
XAIR Analyst Ratings
Bulls say
Beyond Air Inc has demonstrated significant growth in its financial performance, evidenced by a fiscal 3Q26 revenue of $2.2 million, marking a 105% increase compared to previous periods. The company's successful sale of its LungFit PH system to a VA Medical Center and the expansion of its international distribution to 40 countries further enhance its commercial prospects. Additionally, promising interim Phase 1 data for its UNO monotherapy highlights a favorable safety profile and potential therapeutic benefits, reinforcing the company's innovative position in the medical device and biopharmaceutical market.
Bears say
Beyond Air Inc faces challenges in positioning its Nitric Oxide Generator and Delivery System, as management shifts its focus from a niche ablation tool to a potential immunotherapy enhancer, which may complicate its market strategy and commercial acceptance. Additionally, the company's reliance on innovative combinations with existing therapies, like anti-PD-1 treatments, raises uncertainties regarding clinical effectiveness and competitive advantage in a crowded market. Financially, the lack of consistent revenue streams and potential delays in product adoption could hinder growth prospects and investor confidence.
This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.
XAIR Analyst Forecast & Price Prediction
Start investing in XAIR
Order type
Buy in
Order amount
Est. shares
0 shares